Maysa Al-Hussaini

Prof. Maysa Al-Hussaini

Pathology and Laboratory Medicine, King Hussein Cancer Center, Amman, Al ‘Āşimah, Jordan
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2004 in Histopathology
Verified
Journal Article
Closed access
PDF file
MAMaysa Al-Hussaini
Maysa Al-Hussaini
ASA Stockman
A Stockman
HFH Foster
H Foster
WMW G McCluggage
W G McCluggage

17 April 2009 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
MAMaysa Al-Hussaini
Maysa Al-Hussaini
ISIyad Sultan
Iyad Sultan
NANajyah Abuirmileh
Najyah Abuirmileh
IJImad Jaradat
Imad Jaradat
IQIbrahim Qaddoumi
Ibrahim Qaddoumi

1 October 2009 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
ISIyad Sultan
Iyad Sultan
IQIbrahim Qaddoumi
Ibrahim Qaddoumi
CRCarlos Rodríguez‐Galindo
Carlos Rodríguez‐Galindo
ANAnwar Al Nassan
Anwar Al Nassan
KGKhalil Ghandour
Khalil Ghandour
MAMaysa Al-Hussaini
Maysa Al-Hussaini

8 August 2015 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
NANisreen Amayiri
Nisreen Amayiri
UTUri Tabori
Uri Tabori
BCBrittany Campbell
Brittany Campbell
DBDoua Bakry
Doua Bakry
MAMelyssa Aronson
Melyssa Aronson
OCOn behalf of BMMRD consortium
On behalf of BMMRD consortium
Biallelic mismatch repair deficiency (bMMRD) is a cancer predisposition syndrome affecting primarily individuals from consanguinous families resulting in multiple childhood cancers including high grade gliomas (HGG). This is the first study to assess the prevalence of bMMRD among patients with HGG in countries where consanguinity is high. We collected molecular and clinical information on all children diagnosed with HGG and supratentorial primitive neuroectodermal tumors (sPNET) between 2003 and 2013 at King Hussein Cancer Center, Jordan. Comparison was made to a similar cohort from Toronto. Clinical data regarding presence of café au lait macules(CAL), family history of cancer, consanguinity, pathology and treatment were collected. Tumors were centrally reviewed and tested for MMRD by immunohistochemistry of the corresponding proteins. Forty‐two patients fulfilled the inclusion criteria, including 36 with HGG. MMRD was observed in 39% of HGG of whom79% also lost MMR staining in the corresponding normal cells suggestive of bMMRD. P53 dysfunction was highly enriched in MMR deficient tumors (p = 0.0003).The frequency of MMRD was significantly lower in Toronto cohort (23%, p = 0.03). Both evidence of CAL and consanguinity correlated with bMMRD (p = 0.005 and 0.05,respectively) but family history of cancer didn't. HGG with all three bMMRD risk factors had evidence of MMRD and all children affected by multiple bMMRD related cancers had identical gene loss by immunohistochemical staining. In Jordan, the frequency of clinical and immunohistochemical alterations suggestive of bMMRD in pediatric HGG is high. Genetic testing will enable appropriate counseling and cancer screening to improve survival of these patients.

1 July 2004 in International Journal of Gynecological Pathology
Verified
Journal Article
Closed access
VSV. P. Sumathi
V. P. Sumathi
MAMaysa Al-Hussaini
Maysa Al-Hussaini
LCL. E. Connolly
L. E. Connolly
LFL. Fullerton
L. Fullerton
WMW. G. McCluggage
W. G. McCluggage
WT-1 positivity has previously been noted in nonneoplastic endometrial stroma. In this study we examined WT-1 expression in endometrial stromal neoplasms to ascertain whether these tumors are immunoreactive and whether this antibody might be of value in the diagnosis of these lesions. We also stained cases of cellular and highly cellular leiomyomas to investigate whether WT-1 might be of value in distinguishing these from an endometrial stromal neoplasm. We compared WT-1 staining with CD10, desmin, α smooth muscle actin, h-caldesmon, and AE1/3, many of these antibodies being commonly used to distinguish between an endometrial stromal and a smooth muscle phenotype. Cases of ESN (n = 5), low grade ESS (n = 14), and cellular or highly cellular leiomyoma (n = 14) were stained with the aforementioned antibodies. Cases were scored on a scale of 0 to 4+, with 4+ cases exhibiting positivity of >50% of cells. Sixteen of 19 endometrial stromal neoplasms were positive with WT-1, most (14 of 16) with 4+ positivity. Staining was nuclear (5 cases), cytoplasmic (5 cases), or combined nuclear and cytoplasmic (6 cases). All endometrial stromal neoplasms exhibited 4+ staining with CD10. Staining for α smooth muscle actin was present in most cases (14 of 19) and desmin and h-caldesmon were positive in a smaller number of cases (8 and 2 respectively). There was 4+ positivity with desmin in only 1 case. The 2 cases that were h-caldesmon positive both exhibited 1+ staining (<5% cells positive). Six cases were positive with AE1/3, 1 with 4+ staining. Leiomyomatous neoplasms always exhibited 4+ staining with desmin and α smooth muscle actin and in most cases (12 of 14) with h-caldesmon. The other 2 cases exhibited 2+ positivity. Most cases (12 of 14) were positive with WT-1 (7 of 14 with 4+ staining) and CD10 (5 of 14 with 4+ positivity). One case was positive with AE1/3. We conclude that diffuse WT-1 positivity is characteristic of endometrial stromal neoplasms and that this may be of value in diagnosis. However, WT-1 is of limited use in the distinction between an endometrial stromal and a cellular leiomyomatous neoplasm because many of the latter are also positive. This study confirms the value of h-caldesmon in the distinction between an endometrial stromal neoplasm (almost always h-caldesmon negative) and a cellular leiomyomatous neoplasm (h-caldesmon positive). Although CD10 is positive in endometrial stromal neoplasms, the commonly observed immunoreactivity of cellular and highly cellular leiomyomas with this antibody limits its diagnostic usefulness. Desmin is useful as all leiomyomatous neoplasms exhibited diffuse positivity, whereas only a small number of endometrial stromal neoplasms were focally positive and only 1 case exhibited 4+ positivity. Smooth muscle actin is of limited value since most neoplasms studied were positive. The overlapping immunophenotype of endometrial stromal and leiomyomatous neoplasms may reflect the origin of both cell types from a common progenitor within the uterus.

11 March 2024 in Cancers
Verified
Journal Article
Open access
PDF file
RMRazan Mansour
Razan Mansour
Hikmat Abdel-RazeqHikmat Abdel-Razeq
Hikmat Abdel-Razeq
MAMaysa Al-Hussaini
Maysa Al-Hussaini
OSOmar M. Shamieh
Omar M. Shamieh
Akram Al-IbraheemAkram Al-Ibraheem
Akram Al-Ibraheem
AMAsem Mansour
Asem Mansour
This narrative review explores the multifaceted barriers hindering access to quality cancer care in Jordan. A literature-based narrative review was undertaken to explore the current identified barriers to cancer care in Jordan. Four databases were searched using relevant keywords to identify key insights on barriers and proposed solutions. Key challenges and potential solutions were identified based on evidence from studies, reports, and initiatives. Medical services and infrastructure exhibit centralized disparities, impacting rural and underserved areas. Human resources shortages, geopolitical instability, and quality management issues pose significant challenges. Public awareness campaigns face hurdles in addressing the tobacco epidemic and late-stage diagnosis. Socioeconomic disparities, particularly in health insurance and urban–rural divides, further compound barriers. Refugees encounter distinct challenges, including late-stage diagnosis, financial barriers, and psychological distress. Despite multiple challenges, Jordan presents a model for regional development and health equity. This study not only contributes to improving cancer care in Jordan but also offers a roadmap for policymakers, healthcare practitioners, and researchers in similar contexts globally. Government initiatives, financial aspects, and proposed policy measures are examined as potential solutions. Recommendations include coordinated prevention strategies, enhanced screening uptake, training programs, the equitable distribution of facilities, and policy directives aligned with global commitments. The role of digital technologies, telemedicine, and community engagement models is emphasized.